This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sill, J. C. Articles by Folts, J. Search for Related Content PubMed PubMed Citation Articles by Sill, J. C. Articles by Folts, J.

(Circulation. 1997;96:1647-1653.)
© 1997 American Heart Association, Inc.

Articles

Human Platelet Ca²⁺ Mobilization, Glycoprotein IIb/IIIa Activation, and Experimental Coronary Thrombosis In Vivo in Dogs Are All Inhibited by the Inotropic Agent Amrinone

J. C. Sill, MD; B. Bertha, MD; I. Berger, MD; C. Uhl, BS; M. Nugent, MD; ; J. Folts, PhD

From the Department of Anesthesiology, Mayo Clinic, Rochester, Minn (J.C.S., B.B., I.B., C.U.); the Department of Anesthesiology, Medical College of Ohio, Toledo (M.N.); and the Cardiology Section, University of Wisconsin Medical School, Madison (J.F.)

Correspondence to J.C. Sill, MD, Department of Anesthesiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail sill.john{at}mayo.edu

Background Inotropic drugs are often used to treat acute, severe heart failure resulting from acute myocardial infarction and other unstable coronary artery syndromes. However, catecholamine inotropic agents may potentiate coronary thrombosis via a platelet ₂-adrenergic mechanism, thus exacerbating the original problem. The present studies were designed to determine whether the nonadrenergic inotropic and vasodilator drug amrinone, which elevates platelet cAMP levels, would both inhibit human platelet Ca²⁺ mobilization and adhesion molecule expression ex vivo and protect against experimental coronary thrombosis in vivo in dogs.

Methods and Results Human platelets in suspension were preincubated with amrinone 2.5 to 15 µg/mL; stimulated with the agonists thrombin 0.1 U/mL, ADP 10^-6 mol/L, or arginine vasopressin 10^-7 mol/L; and studied for Ca²⁺ mobilization, glycoprotein IIb/IIIa activation, and P-selectin expression by fluorescent flow cytometry methods. Experimental coronary thrombosis in vivo was studied in an open-chest dog model with critical coronary artery stenosis and deep vessel wall injury. Results showed that at the cellular level, amrinone inhibited agonist-induced Ca²⁺ mobilization and had modest inhibitory effects on adhesion molecule expression. In vivo in dogs, intravenous amrinone 2 mg/kg plus infusion at 20 µg·kg^-1·min^-1 completely abolished coronary thrombosis.

Conclusions The fact that amrinone inhibited human platelet activation at the cellular level and protected against experimental coronary thrombosis in vivo in dogs suggests a potentially advantageous antithrombotic action for this inotropic and vasodilator drug.

Key Words: inotropic agents • platelets • thrombosis

This article has been cited by other articles:

				R. Orii, Y. Sugawara, M. Hayashida, Y. Yamada, K. Chang, T. Takayama, M. Makuuchi, and K. Hanaoka Effects of amrinone on ischaemia-reperfusion injury in cirrhotic patients undergoing hepatectomy: a comparative study with prostaglandin E1 Br. J. Anaesth., September 1, 2000; 85(3): 389 - 395. [Abstract] [Full Text] [PDF]